Abstract：OBJECTIVE: To compare the efficacy and safety of tolterodine and oxybutynin in the treatment of idiopathic overactive bladder in children. METHODS: A total of 204 children with idiopathic overactive bladder were randomly divided into three groups (n=68 each): placebo, tolterodine-treated and oxybutynin-treated. The efficacy and safety were evaluated two weeks after treatment. RESULTS: The effective rate was 25% in the placebo group, 89% in the tolterodine-treated group, and 92% in the oxybutynin-treated group. The effective rate in the two treatment groups was significantly higher than that in the placebo group (P<0.05). There was a similar efficacy between the two treatment groups. The incidence of adverse events in the tolterodine-treated group (28%) was significantly lower than that in the oxybutnin-treated group (57%) (P<0.05). CONCLUSIONS: Tolterodine has a similar efficacy to oxybutynin in the treatment of idiopathic overactive bladder in children, with better safety in pharmacotherapy.
DENG Yong-Ji,MA Geng,GUO Yun-Fei et al. Comparisons of efficacy and safety of tolterodine and oxybutynin in children with idiopathic overactive bladder[J]. CJCP, 2011, 13(1): 26-28.
［1］Nevéus T, Von Gontard A, Hoebeke P, Hjalmas K, Bauer S, Bower W, et al. The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardisation Committee of the International Children′s Continence Society［J］. J Urol, 2006, 176(1): 314-324.
［2］Kajiwara M, Inoue K, Kato M, Usui A, Kurihara M, Usui T. Nocturnal enuresis and overactive bladder in children: an epidemiological study［J］. Int J Urol, 2006, 13(1): 36-41.
［3］Hommaa Y, Yoshidab M, Sekic N, Yokoyamad O, Kakizakie H, Gotohf M, et al. Symptom assessment tool for overactive bladder syndrome--overactive bladder symptom score［J］. Urology, 2006, 68(2): 318-323.
［5］Drutz HP, Appell RA, Gleason D, Klimberg I, Radomski S. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder［J］. Int Urogynecol J Pelvic Floor Dysfunct,1999,10(5): 283-289.
［7］Nilvebrant L, Andersson KE, Gillberg PG, Stahl M, Sparf B. Tolterodine--a new bladder-selective antimuscarinic agent［J］. Eur J Pharmacol,1997,327(2-3): 195-207.
［8］Raes A, Hoebeke P, Segaert I, Van Laecke E, Dehoorne J, Vande Walle J. Retrospective analysis of efficacy and tolerability of tolterodine in children with overactive bladder［J］. Eur Urol,2004, 45(2): 240-244.
［9］Hjalmas K, Hellstrom AL, Mogren K, Lackgren G, Stenberg A. The overactive bladder in children: a potential future indication for tolterodine［J］. BJU Int, 2001, 87(6): 569-574.
［10］Nijman R, Borgstein NG, Ellsworth P, Djurhuus JC. Tolterodine treatment for children with symptoms of urinary urge incontinence suggestive of detrusor overactivity: results from 2 randomized, placebo controlled trials［J］. J Urol, 2005, 173(4): 1334-1339.
［11］Kilic N, Balkan E, Akgoz S, Sen N, Dogruyol H. Comparison of the effectiveness and side-effects of tolterodine and oxybutynin in children with detrusor instability［J］. Int J Urol, 2006, 13(2): 105-108.
［12］Bolduc S, Upadhyay J, Payton J, Bagli DJ, McLorie GA, Khoury AE, et al. The use of tolterodine in children after oxybutynin failure［J］. BJU Int, 2003, 91(4): 398-401.
［13］Hoebeke P, De Pooter J, De Caestecker K, Raes A, Dehoorne J, Van Laecke E, et al. Solifenacin for Therapy Resistant Overactive Bladder［J］. J Urol, 2009, 182(4): 2040-2044.
